RC
ABOS icon

Rangeley Capital’s Acumen Pharmaceuticals ABOS Stock Holding History

Rangeley Capital’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$93.5K Hold
35,000
– – 0.09% 153
2026
Q1 		$82.6K Buy
+35,000
New +$89.3K 0.08% 123

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
KIA
Knollwood Investment Advisory Hunt Valley, Maryland $1.12B AUM 41.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Rangeley Capital's ABOS Position: Q2 2026 in Review

Rangeley Capital held its Acumen Pharmaceuticals (ABOS) position steady in Q2 2026 at 35,000 shares worth $93.5K. The position accounts for 0.09% of the portfolio, ranked #153.

Rangeley Capital first reported a position in ABOS in Q1 2026 and has held it in 2 quarters since. 96 funds tracked by Wall St. Rank hold ABOS as of Q2 2026.

  • Rangeley Capital held 35,000 shares of Acumen Pharmaceuticals worth $93.5K as of Q2 2026.
  • Rangeley Capital left its Acumen Pharmaceuticals share count unchanged in Q2 2026.
  • Acumen Pharmaceuticals made up 0.09% of Rangeley Capital's portfolio in Q2 2026, its #153 holding.
  • Rangeley Capital first reported a position in Acumen Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 96 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q2 2026.

Based on Rangeley Capital's 13F filing for Q2 2026, filed 14 Aug 2026.